Updates in Infectious Diseases 2026 Date: Tue, Aug 18th, 2026 Time: 8:00 am - 9:00 am Location: Online
Speakers:
Nishant Prasad, M.D.
Assistant Professor of Clinical Medicine, Weill Cornell Medicine
Attending Physician; Program Director, Infectious Diseases Fellowship
Chief, The Dr. James J. Rahal, Jr. Division of Infectious Diseases, NYPQ
Carl M. Urban, Ph.D.
Director, Infectious Disease Research Laboratory, NYPQ
James Yoon, D.O.
Assistant Professor of Clinical Medicine, Weill Cornell Medicine
Attending Physician; Medical Director, Special Care Clinic
The Dr. James J. Rahal, Jr. Division of Infectious Diseases, NYPQ
Disclosures: None
> Describe the epidemiology of tuberculosis in Queens and identify clinical and systems factors that contribute to delayed recognition and airborne isolation of patients with active tuberculosis at NYPQ.
> Review the clinical spectrum, antimicrobial activity, and anticipated therapeutic role of recently approved antimicrobial agents, including cefepime-zidebactam, intravenous fosfomycin, and tebipenem.
> Apply current evidence-based diagnostic and management principles for infectious encephalitis, including emerging developments relevant to internal medicine practice.
Accreditation
NewYork Presbyterian/Queens is accredited by the Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians.
NewYork Presbyterian/Queens designates this Live Activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
The Medical Society of The State of New York relies upon planners and faculty participants in its CME activities to provide educational information that is objective and free of bias. In this spirit and in accordance with the guidelines of MSSNY, CPME and the ACCME, all speakers and planners for CME activities must disclose any relevant financial relationships with
commercial interests whose products, devices or services may be discussed in the content of a CME activity, that might be perceived as a real or apparent conflict of interest. Any discussion of investigational or unlabeled uses of a product will be identified.